Get the Stockscreener App
335.16
4.23%
-14.81
Pre-market:
311.10
-24.06
-7.18%
Praxis Precision Medicines Inc stock is traded at $335.16, with a volume of 251.06K.
It is down -4.23% in the last 24 hours and up +3.38% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
See More
Previous Close:
$349.97
Open:
$349.44
24h Volume:
251.06K
Relative Volume:
0.64
Market Cap:
$9.34B
Revenue:
$7.46M
Net Income/Loss:
$-303.27M
P/E Ratio:
-24.89
EPS:
-13.4668
Net Cash Flow:
$-249.12M
1W Performance:
-2.44%
1M Performance:
+3.38%
6M Performance:
+81.60%
1Y Performance:
+769.42%
1-Day Range:
$332.18
$349.44
1-Week Range:
$332.18
$366.52
52-Week Range:
$37.19
$366.52
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
335.16 | 9.76B | 7.46M | -303.27M | -249.12M | -13.47 |
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
600.66 | 64.45B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
836.09 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.63 | 40.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
163.68 | 33.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-02-26 | Initiated | Wells Fargo | Equal Weight |
| Dec-15-25 | Reiterated | Oppenheimer | Outperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates - TradingView
Praxis Precision (PRAX) Sees 15% Drop After POWER1 Study Update - GuruFocus
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Praxis Precision Medicines, Inc. announces that its clinical trial has met a key secondary endpoint with a 50% response rate. - Bitget
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), National Health Investors announced on May 26, 2026, that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) for its facility sale tran - Bitget
Praxis Precision Medicines announced that its drug Vormatrigine demonstrated good tolerability in clinical trials. - Bitget
Praxis Precision Medicines reports Phase 2/3 study results for vormatrigine in epilepsy - Investing.com
Praxis reports phase 2/3 epilepsy trial missed primary endpoint By Investing.com - Investing.com India
Praxis (NASDAQ: PRAX) vormatrigine focal seizure study misses main goal but shows signals - Stock Titan
Praxis pauses vormatrigine enrollment after study misses main goal - Stock Titan
FDA Acceptance of Two CNS NDAs Might Change The Case For Investing In Praxis Precision Medicines (PRAX) - Yahoo Finance
Truist Securities maintains Praxis Precision Medicines (PRAX) buy recommendation - MSN
Praxis Precision Medicines (PRAX): Best Mid Cap Stocks to Buy with Highest Upside Potential - Insider Monkey
Trading the Move, Not the Narrative: (PRAX) Edition - Stock Traders Daily
Guggenheim Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $800 - Moomoo
Praxis Precision Medicines stock hits 52-week high at 360.8 USD - Investing.com Canada
10 Best Mid Cap Stocks to Buy with Highest Upside Potential - Insider Monkey
Praxis Precision Medicines stock hits 52-week high at 360.8 USD By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,245 - Moomoo
PRAX Technical Analysis | Trend, Signals & Chart Patterns | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
PRAX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $1245 - GuruFocus
H.C. Wainwright reiterates Praxis Precision stock rating on patent news By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Praxis Precision stock rating on patent news - Investing.com
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $795 - Moomoo
PRAX Reiterated by BTIG -- Price Target Maintained at $843.00 - GuruFocus
Praxis (NASDAQ: PRAX) COO adds shares through Employee Stock Purchase Plan - Stock Titan
Praxis (NASDAQ: PRAX) accounting officer adds shares through employee stock purchase plan - Stock Titan
Praxis (PRAX) CEO acquires 126 ESPP shares as compensation - Stock Titan
Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing. - MSN
HighVista Strategies Sells 69,092 Shares of Structure Therapeutics in Q1 2026News and Statistics - IndexBox
Is FDA NDA Progress Amid Wider Losses Altering The Investment Case For Praxis Precision Medicines (PRAX)? - Yahoo Finance
Needham Reiterates Praxis Precision Medicines (PRAX) Buy Recommendation - MSN
(PRAX) Volatility Zones as Tactical Triggers - Stock Traders Daily
[SCHEDULE 13G] Praxis Precision Medicines, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Point72 entities and Cohen report 0.2% stake in Praxis (PRAX) - Stock Titan
Orbis and Allan Gray report 8.9% stake in Praxis Precision Medicines (PRAX) - Stock Titan
Guggenheim Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - MSN
Praxis Precision Medicines stock (US74006W1036): Biotech innovator in CNS disorders - AD HOC NEWS
Praxis Precision Medicines stock hits 52-week high at $358.01 By Investing.com - Investing.com South Africa
Praxis Highlights FDA NDA Acceptances and Strengthened Cash Runway - TipRanks
Praxis (PRAX) widens Q1 2026 loss while advancing four late-stage CNS drugs - Stock Titan
Praxis Precision Medicines stock hits 52-week high at $358.01 - Investing.com India
Praxis Precision Medicines (NASDAQ:PRAX) Given New $715.00 Price Target at Truist Financial - MarketBeat
Truist Financial Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $715 - Moomoo
HC Wainwright Issues Pessimistic Outlook for PRAX Earnings - MarketBeat
Lifesci Capital Brokers Lower Earnings Estimates for PRAX - MarketBeat
PRAX Stock Price, Quote & Chart | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - ChartMill
Praxis Precision Medicines Maps High-Stakes Launch Path - TipRanks
Wedbush Maintained an Underperform Rating on Praxis Precision Medicines, Inc. (PRAX) - Yahoo Finance
UBS Group AG Sells 7,612 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.00%
3.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):